Overall survival (OS) with encorafenib (enco) plus cetuximab (cetux) in BEACON CRC: Effect of prior therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC)

by on 14 de febrer de 2022 with No hi ha comentaris
  • Desai, J., Kopetz, S., Aderka, D., Grothey, A., Van Cutsem, E., Yaeger, R., . . . Tabernero, J. (2021). Overall survival (OS) with encorafenib (enco) plus cetuximab (cetux) in BEACON CRC: Effect of prior therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC). Asia-Pacific Journal of Clinical Oncology, 17, 119-120 (Meeting abstract)

Deixa un comentari

L'adreça electrònica no es publicarà. Els camps necessaris estan marcats amb *